UroGen Pharma Ltd. (URGN)

NASDAQ: URGN · IEX Real-Time Price · USD
7.19
0.09 (1.27%)
Jan 28, 2022 1:55 PM EST - Market open
Market Cap161.20M
Revenue (ttm)39.83M
Net Income (ttm)-112.89M
Shares Out22.42M
EPS (ttm)-5.07
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume45,471
Open7.07
Previous Close7.10
Day's Range6.71 - 7.33
52-Week Range6.71 - 28.20
Beta1.16
AnalystsBuy
Price Target36.60 (+409.0%)
Earnings Daten/a

About URGN

UroGen Pharma Ltd., a biopharmaceutical company, engages in the development and commercialization novel solutions for specialty cancers and urologic diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102, which is in Phase III clinical trials for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial carcinoma ...

IndustryBiotechnology
IPO DateMay 4, 2017
CEOElizabeth Barrett
Employees198
Stock ExchangeNASDAQ
Ticker SymbolURGN
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 6 analysts, the average rating for UroGen Pharma stock is "Buy." The 12-month stock price forecast is 36.60, which is an increase of 409.04% from the latest price.

Price Target
$36.60
(409.04% upside)
Analyst Consensus: Buy

News

UroGen Pharma to Present at Upcoming Conferences

PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat urothelial and specialty cancers, to...

3 weeks ago - Business Wire

First Patient Dosed in UroGen Pharma's Home Instillation Study of UGN-102 in Patients with Low-Grade Intermediate Ris...

PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat urothelial and specialty cancers, to...

1 month ago - Business Wire

UroGen Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN) a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic diseas...

1 month ago - Business Wire

Urogen Pharma (URGN) Reports Q3 Loss, Misses Revenue Estimates

Urogen Pharma (URGN) delivered earnings and revenue surprises of -7.14% and -28.61%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

UroGen Pharma Reports Third Quarter 2021 Financial Results and Recent Corporate Developments

PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat urothelial and specialty cancers, to...

2 months ago - Business Wire

Earnings Preview: UroGen Pharma

UroGen Pharma (NASDAQ:URGN) is set to give its latest quarterly earnings report on Monday, 2021-11-15. Here's what investors need to know before the announcement.

2 months ago - Benzinga

UroGen Pharma Announces Upcoming 2021 Conferences

PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat urothelial and specialty cancers, to...

2 months ago - Business Wire

UroGen Pharma Unveils New Phase 3 Development Plan for UGN-102 at Spotlight Event

PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat urothelial and specialty cancers, is...

2 months ago - Business Wire

Urogen Pharma (URGN) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

Urogen Pharma (URGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

UroGen Pharma to Host Virtual Spotlight Event on November 10, 2021

PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic disea...

2 months ago - Business Wire

The Journal of Urology Publishes Results of UroGen Pharma's Phase 2b Study of UGN-102 in Patients with Low-Grade Inte...

PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN) today announced The Journal of Urology® published results from the Phase 2b OPTIMA II trial, a Phase 2b, open-label, single-arm trial ...

3 months ago - Business Wire

UroGen Pharma to Present at the 2021 Cantor Virtual Global Healthcare Conference

PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic disea...

4 months ago - Business Wire

UroGen Pharma Presents Data Showcasing Novel Clinical Data at 2021 American Urological Association (AUA) Annual Meeting

PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN) today announced final data from two key trials, evaluating the safety and efficacy of investigational agent UGN-102 (mitomycin) for in...

4 months ago - Business Wire

UroGen Pharma to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic disea...

4 months ago - Business Wire

UROGEN PHARMA (URGN) Reports Q2 Loss, Tops Revenue Estimates

UROGEN PHARMA (URGN) delivered earnings and revenue surprises of -6.36% and 0.25%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

5 months ago - Zacks Investment Research

UroGen Pharma Reports Second Quarter 2021 Financial Results and Recent Corporate Developments

PRINCETON, N.J.,--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic dise...

5 months ago - Business Wire

UroGen Pharma Announces License and Supply Agreement with Neopharm to Pursue Regulatory Approval and Commercializatio...

PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic disea...

5 months ago - Business Wire

UroGen Pharma to Report Second Quarter 2021 Financial Results on Wednesday, August 4, 2021

PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic disea...

6 months ago - Business Wire

UroGen Pharma Reports Strong Preliminary Jelmyto® Sales for Second Quarter 2021

PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic disea...

6 months ago - Business Wire

UroGen Pharma to Present at Ladenburg Thalmann Healthcare Conference

PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd (Nasdaq:URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic disease...

6 months ago - Business Wire

UroGen Pharma Announces June 2021 Conference Schedule

PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic disea...

8 months ago - Business Wire

UROGEN PHARMA (URGN) Reports Q1 Loss, Misses Revenue Estimates

UROGEN PHARMA (URGN) delivered earnings and revenue surprises of 7.14% and -10.96%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

8 months ago - Zacks Investment Research

UroGen Pharma Reports First Quarter 2021 Financial Results and Recent Corporate Developments

PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic disea...

8 months ago - Business Wire

UroGen Pharma to Report First Quarter 2021 Financial Results on Thursday, May 13, 2021

PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic disea...

8 months ago - Business Wire

UROGEN PHARMA (URGN) Reports Q4 Loss, Tops Revenue Estimates

UROGEN PHARMA (URGN) delivered earnings and revenue surprises of -5.34% and 10.46%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

10 months ago - Zacks Investment Research